Mumbai, May 8, 2026: Invicta Diagnostic Limited has completed the acquisition of a 51% equity stake in Vinchurkar Diagnostics Private Limited, marking its entry into the Nashik diagnostics market.
The company informed the National Stock Exchange of India that the acquired shares have been credited to its demat account, completing the first tranche of the transaction that had earlier received board approvals in January, March and April 2026.
The acquisition is part of Invicta’s broader plan to acquire up to 95% stake in Vinchurkar Diagnostics in two phases. The total acquisition cost for the proposed 95% stake is approximately ₹7.6 crore, implying a proportionate consideration of around ₹4.08 crore for the initial 51% acquisition. The remaining stake of up to 44% is proposed to be acquired in a subsequent tranche by October 2026, subject to agreed terms and conditions.
Vinchurkar Diagnostics Private Limited is a Nashik-based diagnostic services provider and the acquisition is expected to strengthen Invicta Diagnostic’s presence beyond the Mumbai Metropolitan Region.